Marshall Wace LLP Has $1.36 Million Position in OPKO Health, Inc. (NASDAQ:OPK)

Marshall Wace LLP grew its position in OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 856.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 921,487 shares of the biotechnology company's stock after acquiring an additional 825,143 shares during the quarter. Marshall Wace LLP owned 0.14% of OPKO Health worth $1,355,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Zacks Investment Management bought a new position in OPKO Health in the fourth quarter worth $49,000. XTX Topco Ltd lifted its holdings in shares of OPKO Health by 79.3% during the 4th quarter. XTX Topco Ltd now owns 194,804 shares of the biotechnology company's stock worth $286,000 after acquiring an additional 86,152 shares during the period. Barclays PLC lifted its holdings in shares of OPKO Health by 68.7% during the 4th quarter. Barclays PLC now owns 916,368 shares of the biotechnology company's stock worth $1,347,000 after acquiring an additional 373,032 shares during the period. Raymond James Financial Inc. bought a new stake in OPKO Health in the fourth quarter valued at about $221,000. Finally, Wells Fargo & Company MN increased its stake in OPKO Health by 14.9% in the fourth quarter. Wells Fargo & Company MN now owns 229,262 shares of the biotechnology company's stock valued at $337,000 after acquiring an additional 29,738 shares during the period. Institutional investors and hedge funds own 64.63% of the company's stock.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 125,000 shares of the business's stock in a transaction on Thursday, April 10th. The shares were bought at an average cost of $1.36 per share, for a total transaction of $170,000.00. Following the transaction, the chief executive officer now owns 214,001,448 shares in the company, valued at approximately $291,041,969.28. This trade represents a 0.06 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have purchased 767,434 shares of company stock worth $1,238,312. Corporate insiders own 49.69% of the company's stock.

Analyst Ratings Changes

A number of research firms have weighed in on OPK. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price objective on shares of OPKO Health in a report on Monday, April 7th. Barrington Research reiterated an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research report on Thursday. StockNews.com upgraded OPKO Health from a "sell" rating to a "hold" rating in a research note on Monday, March 3rd. Finally, JPMorgan Chase & Co. initiated coverage on shares of OPKO Health in a research note on Friday, April 25th. They issued a "neutral" rating on the stock. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $2.75.

OPKO Health Price Performance

OPK stock traded up $0.04 during midday trading on Friday, reaching $1.39. 2,922,263 shares of the company's stock traded hands, compared to its average volume of 3,866,996. The company has a 50-day simple moving average of $1.61 and a two-hundred day simple moving average of $1.57. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a 1-year low of $1.15 and a 1-year high of $2.04. The company has a market cap of $930.10 million, a price-to-earnings ratio of -7.29 and a beta of 1.42.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.03). OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $149.90 million during the quarter, compared to analyst estimates of $163.13 million. During the same quarter last year, the business posted ($0.12) earnings per share. The business's quarterly revenue was down 13.7% compared to the same quarter last year. On average, analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.